The U.S. Food and Drug Administration (FDA) has permitted state-licensed pharmacists to prescribe Pfizer’s (NYSE: PFE) COVID-19 oral antiviral pill Paxlovid to curb rising cases. Shares gained 2.6% on the news and ended the day at $52.75 yesterday. As per a Reuters report, Paxlovid has been approved for use and is freely available as a course of treatment in the U.S. since December 2021. Yet, less than half of the four million courses distributed to pharmacists have been utilized for the treatment. The Protocol for Prescribing Paxlovid Paxlovid is an oral drug to be administered within five days of the onset of symptoms from the virus.
https://www.tipranks.com/news/fda-permits-paxlovid-prescription-by-pharmacists?utm_source=advfn.com&utm_medium=referral
Pfizer (NYSE:PFE)
過去 株価チャート
から 9 2022 まで 10 2022 Pfizerのチャートをもっと見るにはこちらをクリック
Pfizer (NYSE:PFE)
過去 株価チャート
から 10 2021 まで 10 2022 Pfizerのチャートをもっと見るにはこちらをクリック